MedTrace Logo

Incidence of Second Primary Malignancies in Castration-Resistant Prostate Cancer: An Observational Retrospective Cohort Study in the US

NCT02788409 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 2234

Last updated 2019-05-08

No results posted yet for this study

Summary

This study is conducted to estimate population-based incidence rates of second primary malignancies among patients with CRPC similar to those treated with Xofigo. These rates will provide context for second primary malignancy incidence rates from the REASSURE study.

Furthermore this study aims to provide further information about the documentation of bone metastases in Medicare data and the extent of use of only oral androgen deprivation drugs among patients with Medicare Part D coverage, as well as to estimate overall survival of the study population.

Conditions

  • Prostatic Neoplasms

Interventions

OTHER

Not applicable for study

Provide external perspective on background second primary cancer incidence rates for REASSURE study.

Sponsors & Collaborators

  • RTI Health Solutions

    collaborator OTHER

  • Bayer

    lead INDUSTRY

Principal Investigators

  • Bayer Study Director · Bayer

Eligibility

Min Age
65 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-05-15
Primary Completion
2018-05-09
Completion
2018-05-09

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02788409 on ClinicalTrials.gov